Redley LaMar

Independent Biotech Analyst — BiotechSign

I track FDA catalysts, clinical pipelines, and insider signals so you can focus on the trades that matter. Focused on near-term PDUFA dates, convergence signals, and the risk factors most retail investors miss. The biotech market is binary by nature — the patterns around catalyst events are more predictable than most think.